Home / Market News / $AEON
benzinga Corporate Catalyst Impact 75/100 ● positive

AEON Biopharma Says FDA Indicated Prior Head-To-Head Studies Vs. Botox Can Be Submitted As Supportive Evidence For ABP-450 Biosimilar

Sep 30, 2026, 12:01 PM UTC · Primary ticker $AEON

This headline indicates a significant positive development for AEON Biopharma, as the FDA's acceptance of prior head-to-head studies streamlines the regulatory pathway for their ABP-450 biosimilar. This could accelerate market entry and increase competitive pressure on Allergan's Botox. The news suggests a potentially faster and less costly approval process for AEON.

The FDA's indication that prior head-to-head studies can be submitted as supportive evidence is a major de-risking event for AEON Biopharma's ABP-450 biosimilar. This could significantly shorten the development timeline and reduce the cost of bringing the product to market, as it may circumvent the need for new, extensive clinical trials. For AbbVie (owner of Allergan and Botox), this news signals impending competition in a highly lucrative market segment, potentially impacting future revenue and market share for Botox. The pharmaceutical sector, particularly companies with established blockbuster biologics, will be watching this development closely as it sets a precedent for biosimilar approvals.

$AEON positive FDA acceptance of existing data for biosimilar approval
$ABBV negative Increased competition for Botox (Allergan's product)
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.